Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis
June 30, 2022 09:00 ET | Royal Philips
June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis...
NOVARTIS logo.jpg
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
June 30, 2022 04:00 ET | Novartis Pharma AG
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal...
Florida Cancer Specialists & Research Institute Names Colleen Lewis as Vice President of Nursing and Research
June 28, 2022 12:00 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., June 28, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome Colleen Lewis, MSN, ANP-BC, AOCNP to its senior leadership...
theralase_logo_destroying_cancer.png
Theralase Expands Intellectual Property Portfolio
June 28, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
RevolutionLogo.png
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
June 28, 2022 07:00 ET | Revolution Medicines, Inc.
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise,...
Picture1.jpg
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
June 27, 2022 01:00 ET | Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
June 24, 2022 07:13 ET | Novartis Pharma AG
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least...
theralase_logo_destroying_cancer.png
Theralase® Research - One of the Top 10 Most Downloaded Papers
June 24, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
June 23, 2022 11:00 ET | BioNTech SE
First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the...
BioNTech erhält Priority-Medicines (PRIME)-Status der EMA für verstärkte regulatorische Unterstützung des CAR-T-Kandidaten BNT211 zur Behandlung von Hodenkrebs
June 23, 2022 11:00 ET | BioNTech SE
Erster BioNTech-Produktkandidat, der von der Europäischen Arzneimittelagentur den Priority-Medicines (PRIME)-Status erhält; dies ermöglicht eine verstärkte regulatorische Unterstützung bei der...